Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.

摘要: BACKGROUND The purported lack of long term modern prostate brachytherapy outcome data continues to lead many physicians recommend other, more traditional treatments. This concern for results has encouraged the authors supplement their earlier 10-year follow-up patients receiving brachytherapy; in process, an additional 77 (> 50%) were added original cohort, and time was increased by 2 years. METHODS Between January 1987 September 1989, 229 with T1–T3 carcinoma underwent transperineal using iodine-125 (I-125). No patient received adjuvant hormone therapy. The median Gleason sum 5 (range, 2–10). Of these patients, 147 determined have a high probability organ-confined disease treated solely I-125 implant. remaining 82 be at risk extracapsular pelvic external beam radiation addition brachytherapy. All followed continuously. Failure defined as positive biopsy, radiographic evidence metastases, or three consecutive rises specific antigen (PSA) levels American Society Therapeutic Radiology Oncology (ASTRO) consensus article. RESULTS Excluding deaths from intercurrent disease, 122 months 18–144 months). Fourteen excluded analysis due insufficient follow-up. Adopting ASTRO definition failure resulted minimal change survival when compared authors' previous study, which used PSA level > 0.5 ng/mL point. Observed free (DFS) entire cohort 70%. In only group, observed DFS 66%, whereas those achieved 79%. None who full 12 years failed between Years 10 12. Only 25% failures occurred after treatment, thus confirming durability brachytherapy. CONCLUSIONS Prostate provides excellent control few late reported program. appears confer advantages selected patients. Using criteria no significant difference point ng/mL. Cancer 2000;89:135–41. © 2000 Society.